European Academy of Dermatology and Venereology (EADV) Congress 2026
European Academy of Dermatology and Venereology (EADV) Congress 2026
About This Event
The European Academy of Dermatology and Venereology (EADV) Congress 2026 will be taking place.
Location:Vienna Austria
Poster presenting comparative efficacy data for 1.5% ruxolitinib cream versus systemic therapies in moderate atopic dermatitis.
Location:Vienna Austria
Poster presenting 24-week safety and pharmacokinetics results for ruxolitinib cream from the TRuE-AD4 study in adults with moderate atopic dermatitis eligible for systemic therapy.
Location:Vienna Austria
Poster presenting international survey results (TOPiQAL) describing patient profile and multidimensional burden of atopic dermatitis.
Location:Vienna Austria
Poster presenting TOPiQAL international study findings on patient treatment preferences in atopic dermatitis using best-worst scaling.
Location:Vienna Austria
Poster presenting randomized trial and real-world data insights on ruxolitinib cream in moderate atopic dermatitis across disease severity thresholds.
Location:Vienna Austria
Poster presenting long-term TRuE-AD4 results on patient-reported symptom and quality-of-life outcomes with as-needed use of ruxolitinib cream in adults with moderate atopic dermatitis eligible for systemic therapy.
Location:Vienna Austria
Poster presenting item-level patient-reported outcome results from TRuE-AD4 evaluating ruxolitinib cream in adults with moderate atopic dermatitis after failure of topical corticosteroids and topical calcineurin inhibitors.
Location:Vienna Austria
Poster presenting TRuE-AD4 study results on use of ruxolitinib cream to delay or prevent treatment escalation in adults with moderate atopic dermatitis eligible for systemic therapy.
Location:Vienna Austria
Poster presenting pooled Phase 3 STOP-HS1/STOP-HS2 findings characterizing acne in patients with moderate to severe hidradenitis suppurativa treated with povorcitinib.
Location:Vienna Austria
Poster presenting pooled Phase 3 STOP-HS1/STOP-HS2 results on clinical patient-reported and biomarker outcomes with povorcitinib in hidradenitis suppurativa patients with high disease burden.
Location:Vienna Austria
Poster presenting HERALD survey insights on real-world treatment challenges and unmet needs among biologic-experienced European patients with hidradenitis suppurativa.
Location:Vienna Austria
Poster presenting a real-world claims-based algorithm for identifying moderate to severe prurigo nodularis.
Location:Vienna Austria
Poster presenting epidemiology treatment patterns and healthcare resource utilization findings for prurigo nodularis in the US and Germany.
Location:Vienna Austria
Poster presenting exposure-response modeling used to inform Phase 3 dose selection of povorcitinib in nonsegmental vitiligo.
Location:Vienna Austria
Poster describing development of a prospective regulatory-grade disease registry to characterize real-world care for nonsegmental vitiligo.
Location:Vienna Austria
Poster presenting quality-of-life and treatment impact findings from an open-label Phase 2 study of ruxolitinib cream in patients with genital vitiligo.
Location:Vienna Austria
Poster presenting an integrated mixed-effects pharmacokinetics analysis of ruxolitinib cream and implications for safety profile in patients with inflammatory skin diseases.
Why This Event Matters
This conference-style event may feature corporate or industry commentary on strategy, demand, and operating conditions. Investors often monitor sessions for tone and guidance that could influence related stocks, without assuming any specific outcome. The event is listed for October 1, 2026 (America/New_York).
Source summary: The European Academy of Dermatology and Venereology (EADV) Congress 2026 will be taking place.
Location:Vienna Austria -------- Poster presenting comparative efficacy data for 1.5% ruxolitinib cream versus systemic therapies in moderate atopic dermatitis.
Location:Vienna Austria -------- Poster presenting 24-week safety and pharmacokinetics results for ruxolitinib cream from the TRuE-AD4...
This listing is associated with INCY. Market participants may watch these names around the event window for volatility or news flow.
Frequently Asked Questions
- What is European Academy of Dermatology and Venereology (EADV) Congress 2026?
- It is a stock market catalyst entry on Catacal—an event or release investors and traders may monitor. Details are summarized from the cited source and may be updated over time.
- When is European Academy of Dermatology and Venereology (EADV) Congress 2026?
- The calendar shows Oct 1, 2026 (America/New_York). Verify the exact time and any changes using the source link when planning around the event.
- Why does European Academy of Dermatology and Venereology (EADV) Congress 2026 matter for investors?
- Management tone and strategic commentary can affect sentiment even when hard numbers are limited.
- Which stocks or sectors could be affected?
- Symbols linked to this listing include INCY; other names in the same industry group may also move with related news.
- How is this event categorized?
- Catacal groups this entry under "Conference" for navigation. Categories help you find comparable catalysts and build a week-by-week watchlist.
Track Market-Moving Events
Monitor earnings, economic releases, lockups, conferences, and other catalysts that impact stocks.
View Catalyst CalendarComprehensive Calendar
Track earnings, product launches, FDA approvals, economic events, and more.
Impact Ratings
Know which catalysts have the greatest potential to impact stock prices.
Never Miss an Event
Get alerts and reminders so you're always prepared for market-moving events.
View Catalyst Calendar
Track upcoming market events